#FDA

3 AI perspectives

They Called It Impossible for 40 Years — Here's Why I'm Both Thrilled and Furious

Daraxonrasib, the world's first broad-spectrum oral RAS(ON) inhibitor targeting the previously "undruggable" KRAS oncogene, was unveiled at ASCO 2026 as a transformative advance in metastatic pancreatic cancer treatment, drawing a standing ovation after the Phase 3 RASolute 302 trial demonstrated a near-doubling of median overall survival. Across 501 previously treated patients, the trial reported median overall survival of 13.2 months on daraxonrasib versus 6.7 months on chemotherapy — a hazard ratio of 0.40 (p<0.0001), representing a 60% reduction in death risk, with one-year survival rising from 18.7% to 53.3%, marking the first time any second-line agent had pushed median survival past one year in this indication. Unlike sotorasib, which targets only the KRAS G12C variant accounting for just 1–2% of pancreatic cancers, daraxonrasib simultaneously suppresses G12D (40%), G12V (29%), and G12R (15%) — the three mutations responsible for the overwhelming majority of KRAS-driven pancreatic cancer — establishing the proof of concept for broad-spectrum RAS inhibition as a viable therapeutic strategy. This clinical triumph, however, coexists with a structural contradiction: the projected monthly price of $30,547–$37,318 renders the drug effectively inaccessible to 85–90% of the 510,922 annual global pancreatic cancer patients, and the 31-year gap between KRAS discovery in 1982 and the NCI RAS Initiative's launch in 2013 exposes a long history of underfunding — $8,945 in NCI per-death research spending for pancreatic cancer versus $69,800 for breast cancer — that deserves as much attention as the breakthrough itself. Treatment effects vary significantly by individual, and as daraxonrasib is currently available only through expanded access prior to formal FDA approval, all treatment decisions must be made in consultation with a qualified oncologist.

6/21/2026

Lifestyle

Big Food Lost the Vocabulary War. So They Rewrote the Dictionary.

The 2026 FDA announcement of a "non-ultra-processed" food labeling framework marks the culmination of a 20-year corporate strategy to capture the vocabulary of food regulation rather than fight it — a pivot executed after Big Food's 17-year campaign to suppress the NOVA classification system failed in the face of WHO endorsement, Lancet expert consensus, and legislative adoption in Brazil and California. The NOVA system, developed in 2009 by Carlos Monteiro and colleagues at the University of São Paulo, redefined food safety science by measuring risk through the degree of industrial processing rather than individual nutrient composition, creating a framework unfavorable enough to the processed food industry that it inspired a concerted multi-decade campaign to discredit and suppress it at every level of scientific and regulatory discourse. Against that backdrop, the WHO's formal elevation of ultra-processed food to a global health threat in April 2026, the Lancet expert panel's call for immediate policy reform supported by 92 of 104 long-term studies confirming increased chronic disease risks, and peer-reviewed estimates of 124,000 annual preventable U.S. deaths attributable to UPF consumption make the FDA's "non-ultra-processed" label a response that operates structurally in the opposite direction from what the evidence demands. This essay argues that the label does not advance consumer protection but instead follows the precise institutional playbook through which organic certification — originally an independent consumer protection mechanism — was captured by corporate interests and transformed into a premium marketing category over two decades. The defining question of the UPF labeling debate is not scientific — the epidemiological case has cleared the threshold of consensus — but political: who controls the definition of "harmful" in food regulation, and whether that person is sitting with or without the food industry's representatives when the answer is written down.

5/29/2026

Science

The Inconvenient Truth 142,000 People Proved — The Dream of Catching Cancer with a Drop of Blood Is Still Just a Dream

The NHS-Galleri trial with 142,000 participants failed its primary endpoint of reducing late-stage cancer diagnoses, with no mortality data presented. The U.S. signed MCED Medicare legislation despite zero FDA-approved tests, exposing a science-policy divide. At $949 per test, overdiagnosis risks and cost barriers challenge the premise that early detection saves lives.

4/5/2026